Activated estrogens and antiestrogens: A 30-year journey with David Kupfer

Drug Metabolism Reviews

Volumn 38, Issue 1-2, 2006, Pages 117-127

  Jordan, V Craig ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Antiestrogens; DDT; Estrogen receptor; Insecticides; Methoxychlor; Tamoxifen

Indexed keywords

1,1,1 TRICHLORO 2 (2 CHLOROPHENYL) 2 (4 CHLOROPHENYL)ETHANE; ANTIESTROGEN; ENDOCRINE DISRUPTOR; ESTROGEN; ESTROGEN RECEPTOR; INSECTICIDE; METHOXYCHLOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAMOXIFEN CITRATE;

ALKYLATION; BREAST CANCER; COVALENT BOND; DRUG METABOLISM; ESTROGEN ACTIVITY; HUMAN; LIVER CARCINOGENESIS; MICROSOME; NONHUMAN; REVIEW; SUCROSE DENSITY GRADIENT CENTRIFUGATION;

ANIMALS; BIOTRANSFORMATION; ESTROGEN ANTAGONISTS; ESTROGENS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INSECTICIDES; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 33646690059     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.1080/03602530600569893     Document Type: Review

References (64)

1. Adam, H. K., Douglas, E. J., Kemp, J. V. (1979). The metabolism of tamoxifen in humans. Biochem. Pharmacol. 27:145-147.
2. Allen, K. E., Clark, E. R., Jordan, V. C. (1980). Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships. Br J. Pharmacol 71:83-91.
3. Bentrem, D., Fox, J. E., Pearce, S. T., Liu, H., Pappas, S., Kupfer, D., Zapf, J. W., Jordan, V. C. (2003). Distinct molecular conformations of the estrogen receptor alpha complex exploited by environmental estrogens. Cancer Res. 63:7490-7496.
4. Brzozowski, A. M., Pike, A. C., Dauter, Z., Hubbard, R. E., Bonn, T., Engstrom, O., Ohman, L., Greene, G. L., Gustaffson, J. A., Carlquist, M. (1997). Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753-758.
5. Bulger, W. H., Feil, V. J., Kupfer, D. (1985). Role of hepatic monooxygenases in generating estrogenic metabolites from methoxychlor and from its identified contaminants. Mol. Pharmacol. 27:115-124.
6. Bulger, W. H., Kupfer, D. (1978). Studies on the induction of rat uterine ornithine decarboxylase by DDT analogs. I. Comparison with estradiol-17 beta activity. Pest. Biochem. Physiol. 8:253-262.
7. Bulger, W. H., Kupfer, D. (1983). Estrogenic action of DDT analogs. Am. J. Ind. Med. 4:163-173.
8. Bulger, W. H., Muccitelli, R. M., Kupfer, D. (1978a). Interactions of chlorinated hydrocarbon pesticides with the 8S estrogen-binding protein in rat testes. Steroids 32.
9. Bulger, W. H., Muccitelli, R. M., Kupfer, D. (1978b). Interactions of methoxychlor, methoxychlor base-soluble contaminant, and 2,2-bis(p- hydroxyphenyl)-1,1,1-trichloroethane with rat uterine estrogen receptor. J. Toxicol. Environ. Health 4:881-893.
10. Bulger, W. H., Muccitelli, R. M., Kupfer, D. (1978c). Studies on the in vivo and in vitro estrogenic activities of methoxychlor and its metabolites: role of hepatic mono-oxygenase in methoxychlor activation. Biochem. Pharmacol. 27:2417-2423.
11. Bulger, W. H., Muccitelli, R. M., Kupfer, D. (1978d). Studies on the induction of rat uterine ornithine decarboxylase by DDT analogs. II. Kinetic characteristics of omithine decarboxylase induced by DDT analogs and estradiol. Pest. Biochem. Physiol. 27:263-270.
12. Bulger, W. H., Temple, J. E., Kupfer, D. (1983). Covalent binding of [14C]methoxychlor metabolite(s) to rat liver microsomal components. Toxicol. Appl. Pharmacol. 68:367-374.
13. Cole, M. P., Jones, C. T., Todd, I. D. (1971). A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46474. Br. J. Cancer. 25:270-275.
14. Dodds, E. C., Lawson, W. (1936). Synthetic oestrogenic agents without the phenanthrene nucleus. Nature 137:996.
15. EBCTCG. (1988). Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N. Engl. J. Med. 319:1681-1692.
16. Fromson, J. M., Pearson, S., Bramah, S. (1973). The metabolism of tamoxifen (ICI 46,474) Part II in femal patients. Xenobiotica 3:711-713.
17. Greaves, P., Goonetilleke, R., Nunn, G., Topham, J., Orton, T. (1993). Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res. 53:3919-3924.
18. Han, X. L., Liehr, J. G. (1992). Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res. 52:1360-1363.
19. Hard, G. C., Iatropoulos, M. J., Jordan, K., Radi, L., Kaltenberg, O. P., Imondi, A. R., Williams, G. M. (1993). Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Cr1:CD(BR) rats. Cancer Res. 53:4534-4541.
20. Harper, M. J., Walpole, A. L. (1967a). Mode of action of I.C.I. 46,474 in preventing implantation in rats. J. Endocrinol. 37:83-92.
21. Harper, M. J., Walpole, A. L. (1967b). A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J. Reprod. Fertil. 13:101-119.
22. Hoagland, H. (1974). The Road to Yesterday. Worcester, MA.
23. Hunter, R. E., Jordan, V. C. (1975). Detection of the 8 S oestrogen-binding component in human uterine endometrium during the menstrual cycle. J. Endocrinol. 65:457-458.
24. Ireland, J. S., Mukku, V. R., Robison, A. K., Stancel, G. M. (1980). Stimulaation of uterine deoxyribonucleic acid synthesis by 1,1,1-trichloro-2-(p- chlorophenyl)-2-(o-chlorophenyl)ethane (o, p'DDT). Biochem. Pharmacol. 29:1469-1474.
25. Jensen, E. V., Block, G. E., Smith, K., DeSombre, E. R. (1971). Estrogen receptors and breast cancer response to adrenalectomy. Natl. Cancer Inst. Monogr. 34:55-70.
26. Jensen, E. V., Jacobson, H. I. (1962). Basic guides to the mechanism of estrogen action. Recent Progr. Hormone Res. 18:387-414.
27. Jiang, S. Y., Jordan, V. C. (1992). Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J. Natl. Cancer Inst. 84:580-591.
28. Jordan, V. C. (1975). Prolonged antioestrogenic activity of ICI 46, 474 in the ovariectomized mouse. J. Reprod. Fertil. 42:251-258.
29. Jordan, V. C. (2003a). Tamoxifen: a most unlikely pioneering medicine. Nature Reviews Drug Discovery 2:205-213.
30. Jordan, V. C. (2003b). Antiestrogens and selective estrogen receptor modulators as multifunctional medicines Part II: Clinical Considerations and New Agents. J. Med. Chem. 46:1082-1111.
31. Jordan, V. C., Collins, M. M., Rowsby, L., Prestwich, G. (1977). A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J. Endocrinol. 75:305-316.
32. Jordan, V. C., Koerner, S. (1975a). Inhibition of oestradiol binding to mouse uterine and vaginal oestrogen receptors by triphenylethylenes. J. Endocrinol. 64:193-194.
33. Jordan, V. C., Koerner, S. (1975b). Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. Eur. J. Cancer 11:205-206.
34. Jordan, V. C., Schafer, J. M., Levenson, A. S., Liu, H., Pease, K. M., Simons, L. A., Zapf, J. W. (2001). Molecular classification of estrogens. Cancer Res. 61:6619-6623.
35. Juedes, M. J., Kupfer, D. (1990). Role of P-450c in the formation of a reactive intermediate of chlorotrianisene (TACE) by hepatic microsomes from methylcholanthrane treated rats. Drug Metab. Dispos. 18:131-137.
36. Kennedy, B. J. (1965). Hormone therapy for advanced breast cancer. Cancer 18:1551-1557.
37. Kupfer, D. (1975). Effects of pesticides and related compounds on steroid metabolism and function. CRC Crit. Rev. Toxicol. 4:83-124.
38. Kupfer, D. (1976). Interactions of chlorinated hydrocarbons with steroid hormones. Fed. Proc. 35:2603-2608.
39. Kupfer, D., Bulger, W. H. (1976). Studies on the mechanism of estrogenic actions of o, p'DDT: interactions with the estrogen receptor. Pest. Biochem. Physiol. 6:567-570.
40. Kupfer, D., Bulger, W. H. (1977). Interactions of o, p'DDT with the estrogen-binding protein (EBP) in human mammary and uterine tumors. Res. Commun. Chem. Pathol. Pharmacol. 16:451-462.
41. Kupfer, D., Bulger, W. H. (1979). A novel in vitro method for demonstrating proestrogens: metabolism of methoxychlor and o, p'DDT by liver microsomes in the presence of uteri and effects of intracellular distribution of estrogen receptors. Life Sci. 25:975-984.
42. Kupfer, D., Bulger, W. H. (1990). Inactivation of the uterine estrogen receptor binding of estradiol during P-450 catalyzed metabolism of chlorotrianisene (TACE). FEBS Lett. 261:59-62.
43. Levenson, A. S., Catherine, W. M., Jordan, V. C. (1997). Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. J. Steroid Biochem. Mol. Biol. 60:261-268.
44. Levenson, A. S., Jordan, V. C. (1998). The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res. 58:1872-1875.
45. Li, H. C., Mani, C., Kupfer, D. (1993). Reversible and time-dependent inhibition of the hepatic cytochrome P450 steroidal hydroxylases by the proestrogenic pesticide methoxychlor in rat and human. J. Biol. Chem. 8:195-206.
46. Lieberman, M. E., Gorski, J., Jordan, V. C. (1983a). An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro. J. Biol. Chem. 258:4741-4745.
47. Lieberman, M. E., Jordan, V. C., Fritsch, M., Santos, M. A., Gorski, J. (1983b). Direct and reversible inhibition of estradiol-stimulated prolactin synthesis by antiestrogens in vitro. J. Biol. Chem. 258:4734-4740.
48. Lippman, M. E., Chabner, B. A. (1986). National Institutes of Health Consensus Development Conference: Adjuvant chemotherapy and endocrine therapy for breast cancer. Editorial Overview. NCI Monograph 1:5-10.
49. Liu, H., Lee, E.-S., Reyes, A. D. L., Zapf, J. W., Jordan, V. C. (2001). Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor {{alpha}} complex. Cancer Res. 61:3632-3639.
50. MacGregor Schafer, J., Liu, H., Bentrem, D. J., Zapf, J. W., Jordan, V. C. (2000). Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Res. 60:5097-5105.
51. Mani, C., Gelboin, H. V., Park, S. S., Pearce, R., Parkinson, A., Kupfer, D. (1993a). Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-Demethylation and 4-Hydroxylation. Drug Metab. Dispos. 21:645-656.
52. Mani, C., Hodgson, E., Kupfer, D. (1993b). Metabolism of the antimammaary cancer antiestrogenic agent tamoxifen. II. Flavin-containing monooxygenase-mediated N-Oxidation. Drug Metab. Dispos. 21:657-661.
53. Mani, C., Kupfer, D. (1991). Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of flavin-containing monooxygenases in tamoxifen activation. Cancer Res. 51:6052-6058.
54. Mani, C., Pearce, R., Parkinson, A., Kupfer, D. (1994). Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis 15:2715-2720.
55. Murphy, C. S., Parker, C. J., McCague, R., Jordan, V. C. (1991). Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity. Mol. Pharmacol. 39:421-428.
56. Nelson, J. A. (1974). Effects of dichlorodiphenyltrichloroethane (DDT) analogs and polychlorinated biphenyl (PCB) mixtures on 17beta-(3H) estradiol binding to rat uterine receptor. Biochem. Pharmacol. 23:447-451.
57. Ousterhout, J. M., Struck, R. F., Nelson, J. A. (1981). Estrogenic activities of methoxychlor metabolites. Biochem. Pharmacol. 30:2869-2871.
58. Phillips, D. H. (2001). Understanding the genotoxicity of tamoxifen? Carcinogenesis 22:839-849.
59. Phillips, D. H., Carmichael, P. L., Hewer, A., Cole, K. J., Hardcastle, I. R., Poon, G. K., Keogh, A., Strain, A. J. (1996). Activation of tamoxifen and its metabolite alpha-hydroxytamoxifen to DNA-binding products: comparisons between human, rat and mouse hepatocytes. Carcinogenesis 17:89-94.
60. Powles, T. J., Hardy, J. R., Ashley, S. E., Farrington, G. M., Cosgrove, D., Davey, J. B., Dowsett, M., McKinna, J. A., Nash, A. G., Sinnett, H. D. (1989). A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br. J. Cancer 60:126-131.
61. Rouanet, P., Linares-Cruz, G., Dravet, F., Poujol, S., Gourgou, S., Simony-Lafontaine, J., Grenier, J., Kramar, A., Girault, J., Le Nestour, E., Maudelonde, T. (2005). Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen. J. Clin. Oncol. 23:2980-2984.
62. Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., Greene, G. L. (1998). The structural basis of estrogen receptor/co-activator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937.
63. Williams, G. M., Iatropoulos, M. J., Djordjevic, M. V., Kaltenberg, O. P. (1993). The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 14:315-317.
64. Wolf, D.M., Jordan, V. C. (1994). The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Br. Cancer Res. Treat. 31:129-138.